Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE)
Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE)
The purpose of this study is to determine if a subcutaneous dose of DX-88 (ecallantide; an
 investigational product) is safe and relieves symptoms of HAE in patients suffering from
 moderate to severe acute attacks of HAE.
Inclusion Criteria:

 -  Age 10 and older

 -  Documented diagnosis of HAE, Type I or II

 -  Executed informed consent

 -  Presentation for treatment within 8 hours of patient recognition of moderate to severe
 HAE attack

 Exclusion Criteria:

 -  Receipt of investigational drug or device, other than DX-88, within 30 days of
 treatment

 -  Receipt of non-investigational C1-INH (C1 esterase inhibitor) within 7 days of
 treatment

 -  Diagnostic of acquired angioedema, estrogen-dependent angioedema or drug induced
 angioedema

 -  Pregnancy or breastfeeding

 -  Patients who have received DX-88 within 7 days of presentation for dosing in the
 Double-blind Phase